Nitrase Therapeutics

China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis, and screening of DELs to discover compounds that bind to certain targets that are of interest to Nitrase. Under the terms…